Zhu, X., Cao, Y., Liu, W., Ju, X., Zhao, X., Jiang, L., . . . Zhang, H. (2021). Stereotactic body radiotherapy plus pembrolizumab and trametinib versus stereotactic body radiotherapy plus gemcitabine for locally recurrent pancreatic cancer after surgical resection. The Lancet. Oncology, 22(8), p. 1093. doi:10.1016/S1470-2045(21)00286-2
Chicago ZitierstilZhu, Xiaofei, Yangsen Cao, Wenyu Liu, Xiaoping Ju, Xianzhi Zhao, Lingong Jiang, Yusheng Ye, Gang Jin, and Huojun Zhang. "Stereotactic Body Radiotherapy Plus Pembrolizumab and Trametinib Versus Stereotactic Body Radiotherapy Plus Gemcitabine for Locally Recurrent Pancreatic Cancer After Surgical Resection." The Lancet. Oncology 22, no. 8 (2021): 1093.
MLA ZitierstilZhu, Xiaofei, et al. "Stereotactic Body Radiotherapy Plus Pembrolizumab and Trametinib Versus Stereotactic Body Radiotherapy Plus Gemcitabine for Locally Recurrent Pancreatic Cancer After Surgical Resection." The Lancet. Oncology 22.8 (2021): 1093.